logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HER2+ mBCa: capecitabine added to T-DM1 fails to improve outcomes in TRAXHER2 trial

Trial included patients with HER2+ LA/mGC in the phase 1 component.